AKT1 and neoplasm: Among the 27 small molecule inhibitors tested, two EGFR/PI3K dual inhibitors emerged as the most promising ones, with strong effects in modulating tumor cell migration, cell cycle, and proliferation, mechanisms of cell death, morphology, as well as in key players of PI3K/AKT cascade such as MEF2C and FOXP1.